搜索:   联系我们 |  English 


    发布时间:2017-04-29 09:02:31    点击:413

美国Genentech公司科学家学术报告


题目一:Discovery of GDC-0853: A Highly Potent, Selective, and Non-Covalent Btk Inhibitor
报告人:Dr. James Crawford   Genentech
 
题目二:Shuffling Hydrogen: A Completely Atom Economical Solution to Carbonyl Crotylation 
报告人:Dr. Jason Zbieg      Genentech
 
时  间:2017年5月4日(星期四)下午3:30
地  点:仙林化学楼H201报告厅
联系人:朱少林 教授(shaolinzhu@nju.edu.cn)
 
报告人简介:
Dr. James Crawford is a Senior Scientist and Project Team Leader in Small Molecule Drug Discovery at Genentech. Born and raised in Glasgow, Scotland, James attended the University of Strathclyde where he obtained his MSci, followed by his Ph.D., working with Professors Kerr (University of Strathclyde) and Henderson (University of Notre Dame, IN).  In 2005 he joined Professor K.C. Nicolaou’s laboratory at The Scripps Research Institute as a Fulbright scholar. James started his industrial career in late 2006 at AstraZeneca’s Alderley Park site and a move to AZ’s Charnwood site followed, after 4 years with AZ, and having clearly missed the Californian weather, James joined Genentech in San Francisco.  During his time at Genentech, one of his key roles has been as the chemistry leader of the BTK discovery team at Genentech, leading a team co-located in San Francisco and Shanghai.
Dr. Jason Zbieg received a Ph.D. from The University of Texas at Austin (Krische Group) in 2012 with a following Postdoctoral research at Princeton University (Macmillan Group). Jason started his industrial career at Amgen in 2014, then moved to Genentech. Jason’s publication including one first author Science paper.

地址:江苏省南京市栖霞区仙林大道163号南京大学化学楼    邮编:210023    电话:86-25-89682304   传真:86-25-89687761

© 2010-2017   南京大学 化学化工学院